Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$2.60M+3617.14%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eran Ophir
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Beta
- 2.79
- Country
- IL
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -0.00
Financials
Revenue
$2.60M+3617.1%Net Income
$-7.01MEBITDA
$-7.00MFree Cash Flow
$0.00-100.0%EPS (diluted)
$-0.07Shares Outstanding (diluted)
94.64M+85.8%Operating Expenses
$8.74MCash & Debt
$125.30MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $72.76M | $35.34M | $0.38 |
| 2024 | $27.86M | $-14.23M | $-0.16 |
| 2023 | $33.46M | $-18.75M | $-0.21 |
| 2022 | $7.50M | $-33.69M | $-0.39 |
| 2021 | $6.00M | $-34.20M | $-0.41 |
| 2020 | $2.00M | $-29.70M | $-0.37 |
| 2019 | $0.00 | $-27.34M | $-0.43 |
| 2018 | $17.80M | $-22.60M | $-0.41 |
| 2017 | $0.00 | $-37.07M | $-0.72 |
| 2016 | $712.0K | $-31.51M | $-0.62 |
| 2015 | $9.28M | $-20.16M | $-0.40 |
| 2014 | $12.37M | $-11.09M | $-0.23 |
| 2013 | $3.55M | $-14.08M | $-0.36 |
| 2012 | $242.0K | $-13.63M | $-0.38 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.56
- Implied price
- $2.22
- Return from $2.07
- 1.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.11 — -46.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 0 | 2 | 4 | 6 | 8 |
|---|---|---|---|---|---|
| -2.0% | — | -19.9% | -8.0% | -0.2% | 5.7% |
| 3.0% | — | -15.8% | -3.3% | 4.9% | 11.1% |
| 8.0% | — | -11.7% | 1.4% | 10.0% | 16.5% |
| 13.0% | — | -7.6% | 6.1% | 15.1% | 21.9% |
| 18.0% | — | -3.5% | 10.8% | 20.2% | 27.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
20-73.33%Social Signal Score
Mentions (7)
- Newsprnewswire.com·9d ago·Negative
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C.
View source ↗ - Newsmarketbeat.com·10d ago·Negative
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets Compugen NASDAQ: CGEN outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event.
View source ↗ - Newsseekingalpha.com·10d ago·Positive
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
View source ↗ - Newsdefenseworld.net·21d ago·Neutral
Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head Comparison Compugen (NASDAQ: CGEN - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings and Valuation This table compares Compugen and
View source ↗ - Newsprnewswire.com·23d ago·Neutral
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026 HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd.
View source ↗ - Newsprnewswire.com·37d ago·Neutral
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.
View source ↗ - Newszacks.com·45d ago·Positive
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗
Earnings
Mon, Nov 9(in 3 weeks)
Consensus estimate $-0.08 per share
Typical surprise -14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-0.07 vs $-0.08beat
- Mon, May 18$-0.08 vs $-0.07miss
- Mon, Mar 2$0.60 vs $-0.07beat
- Mon, Nov 10$-0.07 vs $-0.09beat
- Wed, Aug 6$-0.08 vs $-0.07miss
- Mon, May 19$-0.08 vs $-0.06miss
Estimates and results for CGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CGEN officers and directors.
- Bought
- —
- Sold
- $118k
0 trades
11 trades
- Levine Zuritsold
- Levine Zuritsold
- Ophir Eransold
- Ophir Eransold
- Levine Zuritsold
- Levine Zuritsold
- Levine Zuritsold
- Levine Zuritsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CGEN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.